These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28316055)

  • 41. Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease.
    Cover KS; van Schijndel RA; Versteeg A; Leung KK; Mulder ER; Jong RA; Visser PJ; Redolfi A; Revillard J; Grenier B; Manset D; Damangir S; Bosco P; Vrenken H; van Dijk BW; Frisoni GB; Barkhof F;
    Psychiatry Res Neuroimaging; 2016 Jun; 252():26-35. PubMed ID: 27179313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
    Davatzikos C; Xu F; An Y; Fan Y; Resnick SM
    Brain; 2009 Aug; 132(Pt 8):2026-35. PubMed ID: 19416949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.
    Deters KD; Risacher SL; Kim S; Nho K; West JD; Blennow K; Zetterberg H; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    J Alzheimers Dis; 2017; 58(4):1245-1254. PubMed ID: 28550246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Automated atrophy assessment for Alzheimer's disease diagnosis from brain MRI images.
    Shaikh TA; Ali R
    Magn Reson Imaging; 2019 Oct; 62():167-173. PubMed ID: 31279772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
    Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
    Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD.
    Spulber G; Niskanen E; Macdonald S; Kivipelto M; Padilla DF; Julkunen V; Hallikainen M; Vanninen R; Wahlund LO; Soininen H
    Curr Alzheimer Res; 2012 May; 9(4):516-24. PubMed ID: 22191564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome.
    Varon D; Barker W; Loewenstein D; Greig M; Bohorquez A; Santos I; Shen Q; Harper M; Vallejo-Luces T; Duara R;
    Int J Geriatr Psychiatry; 2015 Feb; 30(2):192-200. PubMed ID: 24816477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease.
    Tang X; Holland D; Dale AM; Younes L; Miller MI;
    Hum Brain Mapp; 2015 Jun; 36(6):2093-117. PubMed ID: 25644981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Random forest feature selection, fusion and ensemble strategy: Combining multiple morphological MRI measures to discriminate among healhy elderly, MCI, cMCI and alzheimer's disease patients: From the alzheimer's disease neuroimaging initiative (ADNI) database.
    Dimitriadis SI; Liparas D; Tsolaki MN;
    J Neurosci Methods; 2018 May; 302():14-23. PubMed ID: 29269320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does MRI scan acceleration affect power to track brain change?
    Ching CR; Hua X; Hibar DP; Ward CP; Gunter JL; Bernstein MA; Jack CR; Weiner MW; Thompson PM;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1(0 1):S167-77. PubMed ID: 25444601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Josephs KA; Dickson DW; Tosakulwong N; Weigand SD; Murray ME; Petrucelli L; Liesinger AM; Senjem ML; Spychalla AJ; Knopman DS; Parisi JE; Petersen RC; Jack CR; Whitwell JL
    Lancet Neurol; 2017 Nov; 16(11):917-924. PubMed ID: 28919059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.
    Hua X; Hibar DP; Ching CR; Boyle CP; Rajagopalan P; Gutman BA; Leow AD; Toga AW; Jack CR; Harvey D; Weiner MW; Thompson PM;
    Neuroimage; 2013 Feb; 66():648-61. PubMed ID: 23153970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations.
    Evans MC; Barnes J; Nielsen C; Kim LG; Clegg SL; Blair M; Leung KK; Douiri A; Boyes RG; Ourselin S; Fox NC;
    Eur Radiol; 2010 Mar; 20(3):674-82. PubMed ID: 19760240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer's Disease.
    Platero C; Lin L; Tobar MC
    Neuroinformatics; 2019 Jan; 17(1):43-61. PubMed ID: 29785624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One-year Follow-up Study of Hippocampal Subfield Atrophy in Alzheimer's Disease and Normal Aging.
    Madusanka N; Choi HK; So JH; Choi BK; Park HG
    Curr Med Imaging Rev; 2019; 15(7):699-709. PubMed ID: 32008518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy.
    Hagemeier J; Woodward MR; Rafique UA; Amrutkar CV; Bergsland N; Dwyer MG; Benedict R; Zivadinov R; Szigeti K
    Psychiatry Res Neuroimaging; 2016 Sep; 255():87-93. PubMed ID: 27567325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cerebellum shrinks faster than normal ageing in Alzheimer's disease but not in mild cognitive impairment.
    Tabatabaei-Jafari H; Walsh E; Shaw ME; Cherbuin N;
    Hum Brain Mapp; 2017 Jun; 38(6):3141-3150. PubMed ID: 28321950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer's disease imaging biomarker.
    Abrigo J; Shi L; Luo Y; Chen Q; Chu WCW; Mok VCT;
    Acta Radiol; 2019 Jun; 60(6):769-776. PubMed ID: 30185071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rates of cerebral atrophy differ in different degenerative pathologies.
    Whitwell JL; Jack CR; Parisi JE; Knopman DS; Boeve BF; Petersen RC; Ferman TJ; Dickson DW; Josephs KA
    Brain; 2007 Apr; 130(Pt 4):1148-58. PubMed ID: 17347250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.